Bluebird Bio (NASDAQ:BLUE) Shares Up 5.5% on Analyst Upgrade
Bluebird Bio (NASDAQ:BLUE) Shares Up 5.5% on Analyst Upgrade
Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) were up 5.5% during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $3.00 to $4.00. Morgan Stanley currently has an underweight rating on the stock. bluebird bio traded as high as $6.60 and last traded at $6.53. Approximately 3,046,105 shares changed hands during trading, a decline of 37% from the average daily volume of 4,807,327 shares. The stock had previously closed at $6.19.
在摩根士丹利將藍鳥生物股份有限公司(納斯達克代碼：Blue-Get)的目標價從3.00美元上調至4.00美元后，該公司股價週二午盤上漲5.5%。摩根士丹利目前對該股的評級為減持。藍鳥生物的交易價格曾高達6.60美元，最新報6.53美元。約3,046,105股股票在交易中易手，較4,807,327股的日均成交量下降了37%。該股此前收盤價為6.19美元。
Other equities analysts have also recently issued reports about the stock. StockNews.com started coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Royal Bank of Canada decreased their price target on shares of bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, SVB Leerink decreased their price target on shares of bluebird bio from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $6.75.
其他股票分析師最近也發佈了有關該股的報告。股票新聞網站在10月12日星期三的一份研究報告中開始對藍鳥生物的股票進行報道。他們為該公司設定了“賣出”評級。11月8日，加拿大皇家銀行在一份週二的研究報告中將藍鳥生物的目標股價下調至8.00美元，併為該公司設定了“行業表現”評級。最後，SVB Leerink將藍鳥生物股票的目標價從9.00美元下調至8.00美元，並在週一的一份研究報告中為該公司設定了“市場表現”評級。三位股票研究分析師對該股的評級為賣出，六位分析師給出了持有評級，一位分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據，該股的平均評級為持有，平均目標價為6.75美元。
Insider Transactions at bluebird bio
藍鳥生物的內幕交易
In other news, Director Nick Leschly sold 4,290 shares of the stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 9,506 shares of company stock worth $72,088 over the last three months. 2.20% of the stock is owned by company insiders.
其他新聞方面，董事尼克·萊施利在1月11日星期三的一次交易中出售了4,290股該公司股票。這些股票以7.80美元的平均價格出售，總成交額為33,462.00美元。出售完成後，董事現在直接擁有該公司280,149股，價值2,185,162.20美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在這個環節。過去三個月，內部人士總共出售了9,506股公司股票，價值72,088美元。2.20%的股份由公司內部人士持有。
Institutional Investors Weigh In On bluebird bio
機構投資者參與藍鳥生物
bluebird bio Price Performance
藍鳥生物性價比
The firm has a market capitalization of $541.49 million, a price-to-earnings ratio of -1.07 and a beta of 0.99. The business's fifty day simple moving average is $7.40 and its 200 day simple moving average is $6.52.
該公司市值為5.4149億美元，市盈率為-1.07倍，貝塔係數為0.99。該業務的50日簡單移動均線切入位為7.40美元，200日簡單移動均線切入位為6.52美元。
bluebird bio (NASDAQ:BLUE – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $2.25 million. bluebird bio had a negative net margin of 8,828.28% and a negative return on equity of 173.58%. Equities research analysts expect that bluebird bio, Inc. will post -4.36 earnings per share for the current fiscal year.
青鳥生物(納斯達克：Blue-Get Rating)最近一次公佈季度收益是在11月7日(星期一)。這家生物技術公司公佈了該季度每股收益(0.92美元)，比分析師普遍預期的(1.28美元)高出0.36美元。該業務本季度營收為70萬美元，高於分析師預期的225萬美元。藍鳥生物的淨利潤率為負8828.28%，淨資產回報率為負173.58%。股票研究分析師預計，藍鳥生物公司本財年每股收益將達到4.36美元。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司，研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel；用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel；以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- 高收益、高價值的Verizon陷入谷底
- 你應該用這隻反向ETF做空納斯達克100指數嗎？
- 科蒂股票能否在2023年出現上行
- 業內人士買入阿徹航空，這隻股票要起飛了嗎？
- Intuit即將採取行動，但走哪條路呢？
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。